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Ascorbate is a specific co-factor for a large family of enzymes known as the Fe- and 2-
oxoglutarate-dependent dioxygenases. These enzymes are found throughout biology and
catalyze the addition of a hydroxyl group to various substrates.The proline hydroxylase that
is involved in collagen maturation is well known, but in recent times many new enzymes
and functions have been uncovered, including those involved in epigenetic control and
hypoxia-inducible factor (HIF) regulation. These discoveries have provided crucial mecha-
nistic insights into how ascorbate may affect tumor biology. In particular, there is growing
evidence that HIF-1-dependent tumor progression may be inhibited by increasing tumor
ascorbate levels. However, rigorous clinical intervention studies are lacking. This review
will explore the physiological role of ascorbate as an enzyme co-factor and how this mech-
anism relates to cancer biology and treatment. The use of ascorbate in cancer should be
informed by clinical studies based on such mechanistic hypotheses.
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In 1747, James Lind, a surgeon with the British Royal Navy, per-
formed what is considered the first human clinical trial in an
attempt to treat scurvy, administering various potential remedies,
such as cider, vinegar, or sea water to a group of 12 scurvy-stricken
sailors. The only patients to recover were those who received
lemons and oranges, but almost 200 years would pass before the
curative compound was identified as hexuronic acid, later named
ascorbic acid (ascorbate) for its anti-scorbutic (i.e., anti-scurvy)
properties (1). This is commonly known today as vitamin C.
Many of the symptoms of scurvy – gum disease, bleeding, and
poor wound healing – are considered to be the result of defective
collagen production. It was found that the enzyme responsible for
the formation of hydroxy-proline, collagen prolyl-4-hydroxylase
(C-P4H), specifically required ascorbate as a co-factor for its
activity (2). Hence, under conditions of ascorbate-deficiency, C-
P4H loses activity, collagen cannot cross-link sufficiently, and
connective tissues can deteriorate.
Collagen prolyl-4-hydroxylase belongs to the family of enzymes
known as the Fe- and 2-oxoglutarate dependent dioxygenases
(2-OGDDs) that have a wide range of biological functions (3)
(Table 1). In mammalian cells, members of this family modify
hypoxia-inducible factor (HIF) (4), convert dopamine to nora-
drenaline, are involved in the α-amidation of numerous pro-
hormones (5) and carnitine biosynthesis (6, 7). It has more
recently been discovered that 2-OGDDs are epigenetic erasers;
these enzymes hydroxylate methyl-lysine residues on histones
[Jumonji-C domain-containing histone demethylases (JHDMs)]
(8), and ten-eleven translocases (TETs) hydroxylate 5-methyl-
cytosine (9). In addition, RNA and ribosomal hydroxylases have
very recently been characterized (10, 11).
Clearly, the hydroxylation of diverse proteins, DNA and RNA
is proving to be a widespread phenomenon. By the addition
of a hydroxyl group to their respective substrates, 2-OGDDs
are responsible for altering key protein–protein interactions and
nucleic acid structure and function that can result in dramatic
effects on cell signaling, gene expression, and tissue function. As
ascorbate is a specific co-factor for these enzymes, it will be of
great interest to determine how ascorbate availability affects their
function and the consequences for tumor biology. The following
sections will detail the biochemistry of the 2-OGDDs and the activ-
ity of ascorbate as a co-factor, and consider whether this activity
has any relevance to tumor progression.
FE- AND 2-OXOGLUTARATE-DEPENDENT DIOXYGENASES
Despite such large substrate diversity, the catalytic cycle of 2-
OGDDs is thought to be highly conserved (3). The enzymes
are characterized by a core structural motif consisting of eight
β-strands arranged in a “jelly roll” or double-stranded β-helix,
surrounded by α-helices (20). The active site within the double-
stranded β-helix contains a non-haem iron that is coordinated by
a “facial triad” of two histidines and one aspartate/glutamate, with
the remaining three coordination sites occupied by labile water
molecules (20). This is thought to give the catalytic iron a relatively
exposed and flexible arrangement compared to haem oxygenases,
www.frontiersin.org December 2014 | Volume 4 | Article 359 | 1
Kuiper and Vissers Ascorbate as an enzyme co-factor
Table 1 |Various members of the 2-oxoglutarate dioxygenase family in mammalian cells, their known substrates, and biological functions.
Enzyme family/function Enzyme(s) Known substrate(s) Reference
HIF-hydroxylases PHDs 1–3 HIF-α (4)
FIH HIF-α, ARD proteins (12)
Cytosine demethylases TET1–3 5mC (9, 13)
JMJC histone demethylases Numerous – JHDMs, KDMs Methylated histones (14, 15)
DNA and RNA demethylases Numerous – AlkB family, FTO DNA, RNAs, histones (16, 17)
Ribosomal hydroxylases MINA53, NO66, OGFOD1 60S ribosomal proteins (11, 18)
Collagen hydroxylase C-P4H Collagen proline residues (2)
Noradrenalin synthesis D-βH Dopamine (19)
Carnitine synthesis GBBH Trimethyl-lysine (6, 7)
Pro-hormone maturation PHM Peptidyl-lysine (5)
HIF, hypoxia-inducible factor; PHD, prolyl-hydroxylase domain-containing protein; FIH, factor inhibiting HIF; ARD, ankyrin repeat domain-containing proteins; TET,
ten-eleven translocation enzyme; 5mC, 5-methyl-cytosine; JHDM, jumonji histone demethylases; KDM, lysine demethylases; MINA53, Myc-induced nuclear antigen;
OGFOD1, 2-oxoglutarate and iron-dependent oxygenase domain-containing 1; FTO, fat-mass and obesity associated protein; C-P4H, collagen prolyl-4-hydroxylase;
D-βH, dopamine beta-hydroxylase; GBBH, γ-butyrobetaine dioxygenase; PHM, peptidylglycine α-hydroxylating monooxygenase.
allowing for a wide range of catalytic oxidations. However, it may
also make the active site more prone to auto-oxidation (21).
The catalytic cycle (Figure 1A) starts with 2-OG binding, allow-
ing entry of the prime substrate and displacing a water molecule
from Fe2+. Subsequent binding of molecular O2 to Fe2+ catalyzes
the oxidative decarboxylation of 2-OG to succinate and generates a
highly reactive ferryl-oxo species (22) that hydroxylates the prime
substrate, regenerating Fe3+, which is reverted back to Fe2+ fol-
lowed by release of the substrates and CO2. One atom of the O2
is incorporated into the hydroxylated substrate and the other into
succinate. The CO2 is derived from the oxidative decarboxylation
of 2-OG to succinate (3, 20). Ascorbate is a necessary co-factor for
this reaction, and although its role remains to be determined, it is
thought to be required to maintain Fe2+ in its reduced state.
Well-characterized members of the 2-OGDD family now
include the HIF-hydroxylases (20). These enzymes are thought
to have particular relevance to tumor biology due to their direct
effects on HIF activation. HIF-1 is a transcription factor known
to up-regulate hundreds of genes involved in maintaining oxy-
gen and energy homeostasis under conditions of cell stress, such
as hypoxia – a common feature of solid tumors (23). The acti-
vation state of HIF-1 is under dual control, with HIF-1α protein
stability and transcriptional activity being regulated by hydroxy-
lation reactions. HIF-1α protein is constantly synthesized in most
cells in the body, and under normal, physiological conditions is
rapidly degraded (24) following hydroxylation of proline residues
402 and 564 by prolyl-hydroxylases (PHD) 1–3 (25, 26) (Table 1).
This modification initiates ubiquitination and proteasomal degra-
dation via binding of the tumor-suppressor von Hippel–Lindau
protein (pVHL) and an E3 ubiquitin ligase complex (27, 28).
A further hydroxylation event on asparagine 803 of HIF-1α
by factor inhibiting HIF (FIH; Table 1) prevents co-activation
with p300 and transcriptional activation (29). These events com-
bine to enable a rapid response to cell stressors, where a decrease
in hydroxylation activity immediately halts HIF-1α degradation,
both allowing the protein to accumulate and also to activate a tran-
scriptional response (20). The activation of HIF-1 is, therefore,
dependent upon the activity of the hydroxylases responsible for
modification of the HIF-1α subunit.
2-OGDD REGULATION AND CO-FACTOR DEPENDENCE
The requirements for the 2-OGDD catalytic cycle (O2, Fe2+, 2-
oxoglutarate, and ascorbate) provide clues as to the physiological
conditions that might affect 2-OGDD activity (Figure 1B).
Although the HIF-hydroxylases clearly respond to changes in
cellular O2 levels and are considered direct cellular oxygen sen-
sors, it is currently unknown whether other 2-OG dioxygenases are
similarly sensitive. An example of this has recently been described:
in tumorigenic neuroblastoma cells, TET1 was shown to be up-
regulated under hypoxia via HIF-1, and to cause increased 5hmC
levels specifically at HIF-binding sites, suggesting a synergistic
relationship (30). This is somewhat counter-intuitive, as hypoxia
would also be expected to inhibit TET activity and 5hmC for-
mation. However, whether the TET catalytic cycle is sensitive to
O2 changes is yet to be shown. This highlights the complexity of
2-OGDD biology, with each enzyme and isoform having distinct
activity dynamics despite sharing a highly conserved active site.
Iron is also a necessary co-factor for 2-OGDD activity, and its
substitution/depletion can disrupt HIF-hydroxylase activity and
activate the HIF-1 response. Iron chelators such as desferrioxam-
ine (DFO), and Co2+ and Ni2+ ions robustly induce HIF-1, and
this is thought to be through poisoning of the hydroxylases via
removal of enzyme-bound iron (4, 26, 31). The apparent Km val-
ues for Fe2+ are low, with 0.03µM for PHD1 and 2, 0.1µM for
PHD3 (32) and 0.5µM for FIH (33). This suggests tight binding
of Fe2+ to the HIF-hydroxylase active site, despite the coordi-
nation chemistry predicting a labile arrangement (21). However,
whether Fe3+ produced during enzymatic cycling has the same
tight binding as Fe2+ is unknown.
2-OG (also known as α-ketoglutarate) is an intermediary
metabolite of the TCA cycle. Other 2-oxoacids from the TCA cycle,
such as succinate and fumarate, can compete with 2-OG to inhibit
HIF-hydroxylase activity and induce HIF-1 in vitro (34). Pyruvate,
oxaloacetate, and malate have also been shown to have similar
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FIGURE 1 | 2-Oxoglutarate-dependent dioxygenase reaction cycle and
factors affecting their activity in mammalian cells. (A) Representation
of 2-OGDD catalytic cycle. One atom of molecular oxygen is incorporated
into the hydroxylated substrate and the other into succinate. 2-OG is
converted to succinate, releasing CO2. Ferrous iron and ascorbate are
specific co-factors for this reaction. (B) Cellular stressors deprive
2-OGDDs of their required co-factors resulting in inhibition of multiple
potential pathways.
HIF-1-inducing effects, and may cause significant basal HIF-1
activation under normoxic conditions (35, 36). HIF-1 activity
can be increased by mutations in the TCA cycle enzymes succi-
nate dehydrogenase and fumarate dehydrogenase, which cause a
build-up of succinate and fumarate, respectively (37). Further-
more, mutated forms of isocitrate dehydrogenase-1 generate 2-
hydroxyglutarate (2-HG) that acts as a competitive inhibitor of
the HIF-hydroxylases and activates HIF-1 (38, 39). These muta-
tions have the potential to drive non-hypoxic HIF-1 activity
and tumorigenesis (40), and have been clinically associated with
the susceptibility to renal cancer and paragangliomas (38). The
availability of glycolytic and energy intermediates may confer a
complex metabolic-sensing role to the HIF-hydroxylases. How-
ever, exactly which 2-oxoacids are relevant under physiological
conditions, and to what degree, is unknown.
It has been suggested that the HIF-hydroxylases can be inac-
tivated by production of reactive oxygen species produced by
mitochondria in response to hypoxia (41). There is evidence that
HIF-hydroxylase activity can be inhibited by H2O2, inducing HIF-
1 in a process requiring functional mitochondria, although the
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precise mechanisms behind this are unclear (35, 42–44). Con-
versely, mitochondrial H2O2 production has been shown to be
decreased in response to hypoxia (45) and another study found no
association between levels of reactive oxygen species (DCF fluo-
rescence) and HIF-1 target gene expression (46). FIH was shown
to be sensitive to H2O2-mediated inactivation, whereas PHD2
was not, providing an explanation for some of these effects (47),
where H2O2 could influence transcriptional inactivation of HIF-1
without affecting its protein stability.
ASCORBATE AS REGULATOR OF 2-OGDD ACTIVITY
The Km values for ascorbate for the HIF-hydroxylases and C-
P4H are relatively high [140–300µM (33, 48, 49)], indicating
high intracellular requirements and susceptibility to ascorbate loss.
However, the exact role of ascorbate in the hydroxylase reaction
is unclear. Most data on ascorbate and hydroxylase activity had
come from studies in the 1970–1980s on purified C-P4H in the
context of collagen proline-hydroxylation that may also be relevant
to other 2-OGDDs (22, 50).
Ascorbate was found to be important, if not essential, for
C-P4H activity, with an optimal concentration of 1–2 mM (49,
51–55). In its absence, C-P4H could catalyze only ~15–30 reac-
tion cycles over 8 s before the reaction ceased, and addition of
1 mM ascorbate to the reaction mixture rescued 100% of enzyme
activity (2). Another study found C-P4H had a 54% lower ini-
tial reaction rate in the absence of ascorbate, which decreased
to ~8% of total activity within 30 s with subsequent ascorbate
addition able to rescue partial activity (51). Others have found
no C-P4H activity without ascorbate, demonstrating an absolute
requirement for this co-factor (54, 55). Furthermore, ascorbate
was needed for activity prior to 2-OG addition, suggesting that
under constant turnover conditions, a permanent ascorbate pres-
ence is required (51, 54). Although these results may be influenced
by variation in co-substrate concentrations or order of addition, it
is clear that ascorbate has a significant effect on hydroxylase activ-
ity, with recombinant PHD2 activity having also been shown to
increase dose-dependently with ascorbate (56).
Several recent independent studies have demonstrated the spe-
cific requirement of ascorbate for TET activity, with a consequent
widespread effect on DNA demethylation (57–60). TET enzymes
catalyze the conversion of 5mC to 5hmC,which can then be further
oxidized and converted to an unmodified (demethylated) cyto-
sine. There was a dose-dependent increase in 5hmC levels of up
to fourfold above baseline in ascorbate-treated cells (0–1000µM)
(59, 60), which was mediated by the catalytic domain of TET1 and
2 (60). In addition, the reaction rate of TET2 increased eightfold in
the presence of ascorbate (60). Ascorbate-treated mouse embry-
onic stem cells showed dramatic erasure of 5mC marks (32–40%
decrease) over 3 days of treatment (60). These studies indicate
that intracellular ascorbate availability is likely to have significant
implications for cell reprograming and cancer cell biology.
MECHANISM OF ASCORBATE ACTIVITY
The mechanism by which ascorbate enhances hydroxylase activ-
ity has been thought to be due to the specific reduction of
enzyme-bound Fe3+ to Fe2+. Uncoupled reaction cycles may
be the primary cause of iron oxidation and although these
represented only 0.7 or 1.25% of total C-P4H activity, this was
found to be sufficient to oxidize enzyme-bound iron (49, 55). This
oxidation could be reversed by ascorbate (51, 53, 55). Ascorbate
is not stoichiometrically consumed during hydroxylase activity
(54, 55), but one study found that it was stoichiometrically con-
sumed specifically during uncoupled reaction cycles, supporting
its involvement in protecting against this mode of enzyme inacti-
vation (53). However, in another study, using recombinant PHD2,
there was a significant increase in ascorbate-reversible Fe3+ only
when the prime substrate was added, suggesting coupled turnover
may also oxidize the iron (61).
We have shown that ascorbate was able to prevent induction of
HIF-1α by Co2+, Ni2+, or iron chelation by DFO (62). DFO specif-
ically chelates Fe3+ (63), which is formed during the hydroxylase
reaction cycle, and the prevention of which suggests that ascorbate
may prevent free loss of enzyme-bound Fe3+ or its substitution
with Co2+ or Ni2+ (64). Ascorbate is known to interact with iron
by reducing insoluble ferric iron complexes to stable, soluble, fer-
rous chelates (65, 66) and can chelate iron intracellularly (67).
Together, these studies would support a specific role for ascor-
bate in both chelating and reducing enzyme-bound Fe3+ during
hydroxylase reactions to maintain continued enzyme cycling.
This specificity of ascorbate for optimizing hydroxylase activity
has been demonstrated; other reducing agents including glu-
tathione, vitamin E, NADPH, dithiothreitol (DTT), L-cysteine,
and tetrahydrofolic acid, were unable to substitute for ascorbate for
C-P4H or TET activity (2, 54, 55, 59, 60). In addition, ascorbate was
specifically necessary for full substrate hydroxylation with the HIF-
hydroxylases (purified recombinant PHD2 and FIH), substantially
increasing both the initial rate and extent of HIF-1α domain
hydroxylation (68). Glutathione and DTT were not able to sub-
stitute for ascorbate, although DTT (68) and supra-physiological
concentrations of glutathione in combination with ascorbate (69)
can partially enhance PHD2 hydroxylase activity. These studies
demonstrate that ascorbate is the most effective reducing agent
for hydroxylase activity, with a high degree of specificity.
Ascorbate may also be structurally specific to the hydroxylase
active site. There is some support for its direct binding to the active
site iron in C-P4H, where it may act as an inner-sphere reductant
for the iron (49, 52) and a plausible ascorbate binding site within
the enzyme–substrate complex has been reported for a plant mem-
ber of the 2-OGDD family, anthocyanidin synthase (70). This
provides a further possible mechanism for ascorbate, where it may
stabilize the enzyme–substrate interaction to facilitate hydroxylase
activity. Further to this, a recent study on the AlkB protein indi-
cates it has highly dynamic protein folding depending on whether
2-OG and Fe2+ are bound (71), and it has been suggested that the
TET enzymes require ascorbate to assist functional protein folding
to enhance catalytic activity (60). The effect of ascorbate structural
analogs on PHD2 and FIH activity revealed that the enediol reduc-
ing moiety of ascorbate is essential for hydroxylase activity (68),
supporting its role in maintaining reduced Fe2+. However, the
precise binding position of ascorbate in the hydroxylase reaction
cycle is still unclear.
In summary, there is a growing number of 2-OGDD family
members with various cellular functions, and in those that have
been studied (C-P4H, HIF-hydroxylases, and TETs), it is clear that
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ascorbate is required to maintain their activity. Whether other
2-OGDDs are similarly dependent on ascorbate for activity, and
how that affects the relevant cellular pathways, will be of interest
to investigate.
ASCORBATE BIOCHEMISTRY AND PHARMACOKINETICS
2-oxoglutarate dependent dioxygenases appear to require above
1 mM intracellular ascorbate for optimal activity, and interestingly,
most cells in the body will accumulate these levels under normal,
healthy physiological conditions. In most organisms, ascorbate is
synthesized from glucose. Animals produce ascorbate in the liver
or kidneys, from which it is transported to the plasma for distri-
bution to the rest of the body (72). However, primates, including
humans, as well as guinea pigs and some species of bat are unable
to synthesize it due to evolutionary loss of the terminal synthetic
enzyme, gulonolactone oxidase (72). Therefore, ascorbate is an
essential nutrient (vitamin C) that we must obtain from our diet.
Many of the known functions of ascorbate are attributable
to its action as an electron donor. Ascorbate has two ionizable
hydroxyl groups with pKa values of 4.2 and 11.6, meaning at phys-
iological pH, it is present as the ascorbate monoanion (Figure 2)
(73). It readily undergoes two consecutive, reversible, one-electron
oxidations, resulting in the ascorbate radical and dehydroascor-
bate (DHA; Figure 2) (73). Ascorbate is an excellent antioxidant,
both thermodynamically and kinetically, is able to neutralize many
highly reactive oxidizing species, and is therefore known as a
terminal small molecule antioxidant (74).
Tissue ascorbate levels vary significantly and this is generally
thought to reflect a functional requirement. The highest levels
are found in the adrenal medulla where noradrenaline is syn-
thesized and in the pituitary gland where many hormones are
produced (75). The brain also has high levels and is the last organ
to be depleted during deficiency (76), and many other tissues,
including white blood cells, contain high concentrations. Tissue
ascorbate levels are maintained by specific active transporters iden-
tified as sodium-dependent vitamin C transporters (SVCTs), with
two known isoforms – SVCT1 that is specifically involved in gas-
trointestinal absorption and renal reabsorption, and SVCT2 that
expressed in most tissues and is thought to be responsible for
whole body cellular uptake (77, 78).
Plasma ascorbate saturation from gastrointestinal absorption
is ~100µM and the SVCTs transport it against a concentra-
tion gradient resulting in millimolar intracellular concentrations
(79–81). Final intracellular ascorbate levels depend on the circu-
lating plasma concentration available to the cells for uptake. The
apparentKm values for the SVCTs have been determined in various
cultured human cell lines, and range between 65 and 237µM for
SVCT1 and 8–62µM for SVCT2, the primary mediator of intra-
cellular uptake (82). An optimal plasma level to achieve tissue
saturation is ~70–80µM, which corresponds to a dietary intake of
~200 mg per day and tissue accumulation becomes significantly
impaired if plasma levels fall below ~20µM (83). This suggests
that access to concentrations in the range of those found in plasma
will substantially affect intracellular levels. Interestingly, several
studies have shown that cancer patients have significantly lower
plasma ascorbate levels compared to healthy controls (84–89) and
this may limit tumor cell uptake.
ASCORBATE IN TUMOR TISSUE
The ascorbate content of tumor tissue has been measured in some
studies as early as the 1970s, with variable results. Brain and col-
orectal tumors contained significantly less ascorbate than normal
tissue (90–92) whereas breast (93), oral (87), skin (94), and lung
(84) cancers had significantly more ascorbate than corresponding
normal tissues.
More recent studies from our lab have shown that both
endometrial and colorectal tumors of high histological grade had
less ascorbate than matched, adjacent normal tissue (95, 96). This
may be due to a disorganized vessel network common in high
grade tumors, or may reflect a reduction in expression or activity
of SVCT2, which is known to vary among cancer cell lines (97),
but to our knowledge, has not been examined in human cancer
tissue.
Given the difficulty of accessing the plasma supply, it is possi-
ble that delivery of ascorbate to tumor cells may be compromised.
Plasma levels are tightly controlled by the SVCTs, limiting absorp-
tion and reabsorption at both the intestine and kidney and do not
normally exceed ~100µM with dietary intake (83). Intravenous
administration of ascorbate bypasses this tight control and can
yield plasma levels up to 100-fold higher with maximum levels of
up to 15 mM (98). Whether these supra-physiological concentra-
tions would significantly increase delivery to tumor cells or cellular
uptake is unknown, but investigation of this possibility may be of
particular relevance to cancer.
POTENTIAL 2-OGDD-MEDIATED EFFECTS OF ASCORBATE ON
TUMOR BIOLOGY
ASCORBATE AND HIF-1 REGULATION
Several in vitro studies have shown that ascorbate (25–1000µM
in culture medium) can suppress HIF-1α protein stabilization
FIGURE 2 | Chemical structures of ascorbate and its oxidation products. At physiological pH, ascorbate exists as the ascorbate monoanion and can
undergo two consecutive, reversible, one-electron oxidations to produce the ascorbate radical and dehydroascorbate, respectively. Adapted from Kall (73).
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and transcriptional activity due to CoCl2 (62, 99, 100), DFO
(62, 100), and insulin-like growth factor or insulin (100). The
response to hypoxia is less clear, with some of these studies report-
ing that ascorbate could inhibit HIF-1 at 1–3% O2 (62, 99–101),
while other results showed no effect of ascorbate at ≤1% O2
(36, 100). Ascorbate was also able to completely block basal HIF-
1α present in oncogenically activated cells that had mutant p53
and PTEN, indicating that it is able to enhance HIF-hydroxylase
catalytic capacity in order to cope with the increase in HIF-1α
synthesis (100).
One in vivo study has measured xenograft growth in mice of
P493 cells that constitutively expressed a mutant, stabilized form
of HIF-1α (102). Oral ascorbate supplementation of the animals
resulted in significant inhibition of wild-type tumor growth, with
no effect on mutant HIF-1α tumors (102). Interestingly, the mice
in this study were able to synthesize their own ascorbate, and the
control group also had reduced tumor growth compared to the
mutant HIF-1α group (102). This indicates that ascorbate can
inhibit HIF-1-mediated tumor growth in mice, and that higher
concentrations have a greater effect. However, the plasma and tis-
sue concentrations were not reported. To our knowledge, this is
the only animal study to determine the HIF-1-dependent effects of
ascorbate on tumor growth, and more data measuring HIF-1 and
tumor ascorbate levels in a similar model would be particularly
valuable.
We have correlated tumor ascorbate content with HIF-1 acti-
vation in human tumor tissue and, to our knowledge, these are
the only studies to date to have done so. Strikingly similar patterns
were seen in endometrial and colorectal cancer, with a significant
inverse relationship between tumor ascorbate levels and HIF-1
activation (95, 96). We also measured disease-free survival in the
colorectal cancer cohort and found that patients who had low
tumor ascorbate content had shorter disease-free survival (95).
This relationship was seen in a relatively small group of 50 patients,
and was independent of tumor grade and stage, indicating that
ascorbate may play a significant role in curbing tumor progression.
Interestingly, the ascorbate content of adjacent normal tissue was
not related to disease-free survival, suggesting that it is the ascor-
bate content of the tumor itself that is important (95). The precise
mechanism behind this observation requires further clinical inves-
tigation including measurement of various 2-OGDD-regulated
pathways in relation to changes in tumor ascorbate content.
ASCORBATE AND EPIGENETIC REPROGRAMING
The regulation of HIF-1 is likely to contribute to the anti-tumor
activity of ascorbate (102). However, the recent discovery of the
dependence of the TET enzymes on ascorbate for activity indicates
that it may also act to epigenetically reprogram cancer cells. Ascor-
bate was observed to enhance generation of mouse and human
pluripotent stem cells (103). Subsequently, the histone demethy-
lase Jmjd1 was found to be involved in the ascorbate-dependent
demethylation of pluripotency genes (104), and furthermore,
modulation of TET activity by ascorbate has been implicated in
somatic cell reprograming (57, 58). This has become a highly com-
plex field, with dynamic interplay between TET expression levels
and ascorbate availability (58), and also TET expression and HIF-1
activity (30). This raises interesting questions about how ascorbate
levels in cancer cells could affect the epigenetic phenotype. In addi-
tion, as hypoxia may be coincident with ascorbate-deficiency, this
could alter the response significantly.
The JHDM and AlkB sub-families of 2-OGDDs are also poten-
tial regulators of these processes, and it is unknown how many of
them are affected by changes in availability of co-factors. Ascorbate
would seem to have broad range of potential targets in a cancer
cell, many of which may be currently uncharacterized, where the
overall effect could “tip the balance” of signals and push cancer
cells toward cell death.
ASCORBATE AND CANCER
Ascorbate has a controversial history in relation to cancer treat-
ment. In the 1970s, Ewan Cameron and Linus Pauling used both
intravenous and oral ascorbate to treat 100 advanced cancer
patients and found significant improvements in survival time and
quality of life (105, 106). Subsequently, the Mayo Clinic sought
to further investigate their findings by performing randomized,
double-blind, placebo-controlled studies, using only oral ascor-
bate, initially with 60 advanced cancer patients who had received
prior chemotherapy (107), or later in 100 colorectal cancer patients
who had not received prior treatment (108). These clinical tri-
als found no difference between ascorbate and the placebo, and
ascorbate as a cancer therapy was effectively dismissed.
The recent discovery that intravenous ascorbate administration
can provide 100-fold higher plasma levels compared to oral intake
has renewed interest in its potential in treating cancer (98). Four
credible case studies (including prostate cancer, renal cell carci-
noma, bladder cancer, and B-cell lymphoma) have been reported
showing intravenous ascorbate had substantial anti-cancer activ-
ity in these advanced cancer patients (109, 110), three of which
were evaluated in accordance with the National Cancer Institute
Best Case Series guidelines (110). However two recent studies,
both with 24 patients and no control population, have shown no
objective response, with the exception of three patients who had
stable disease (111, 112). None of these studies have monitored
tissue ascorbate levels or any biological markers other than toxic-
ity parameters, and have been performed in an unselected patient
population. Nevertheless, studies have found that high-dose ascor-
bate is remarkably non-toxic and well-tolerated in patients with
normal renal function (111–113), a rare and valuable trait in a
potential cancer therapy. This, together with evidence that some
cancer patients may benefit from ascorbate treatment, should
be grounds for further rigorous clinical investigations, based on
sound hypotheses.
The renewed interest for a role for ascorbate in cancer has gen-
erated a growing body of in vitro and animal studies to determine
its effectiveness against cancer cell survival and tumor growth,
particularly using high millimolar doses (79). One hypothesis
to support the use of high-dose ascorbate is the finding that at
these pharmacological concentrations, it may act as a prodrug
to deliver extracellular H2O2 that is selectively toxic to cancer
cells (114, 115).
Recent animal studies have investigated the effect of ascor-
bate and tumor growth, all using different dosing regimens and
tumor models (116–120). However, they have consistently shown
an anti-tumor effect of ascorbate supplementation in mice. Mouse
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studies that used pharmacological ascorbate dosing (intravenous
or intraperitoneal) showed a reduction in tumor growth rate and
volume (116, 119–121). Other studies have used the Gulo−/−
mouse model, in which the animals cannot synthesize ascor-
bate, to investigate the effect of physiological ascorbate levels
(117, 118), and have also shown inhibition of tumor growth
in orally ascorbate-supplemented mice. A very recent Gulo−/−
study showed that physiological ascorbate supplementation dra-
matically reduced tumor metastases and necrosis, features that
were associated with MMP-9 (a HIF-1 target gene) expression and
tumor invasiveness (122). Serum VEGF levels were also markedly
reduced (122). These mouse studies support a role for ascorbate
in inhibiting tumor progression, and although the mechanisms
behind some of these effects may need further clarification, the
inhibition of HIF-1 is likely to contribute (102) (Figure 3).
The promise of ascorbate in treating cancer may lie in its
combined use with other chemo-therapeutics. HIF-1 is known
to be a driver of both chemo- and radio-resistance (123) and
boosting intracellular ascorbate levels in the tumor may inhibit
this effect and enhance the effectiveness of current treatments.
There has been some concern that ascorbate, which is a versatile
antioxidant, may in fact counteract the oxidative damage against
cancer cells caused by some current cancer therapies, thereby
limiting their effectiveness (124). However, recent in vitro and
in vivo studies have shown that ascorbate can, in fact, enhance
the effectiveness of chemotherapy (120, 125, 126). Pre-treatment
of prostate cancer cells with physiological ascorbate concentra-
tions significantly reduced the IC50 values of docetaxel and 5-
fluorouracil (126) and pharmacological dosing of ascorbate in
mice synergized with gemcitabine resulting in significantly inhib-
ited tumor growth (125). In addition, a recent phase I clinical trial
of high-dose intravenous ascorbate with gemcitabine and erlotinib
in advanced pancreatic cancer has shown no adverse effects of
including ascorbate (127). To our knowledge, no studies have
examined the effect of intracellular ascorbate on HIF-1-induced
treatment resistance. It would be of interest to study the response
of tumor cells with an active HIF-1 response to a range of chemo-
therapeutics, and monitor drug effectiveness in ascorbate-deficient
or pre-loaded cells.
CONCLUSION
The control of the 2-OGDDs by ascorbate has the potential to
impact tumor growth at all stages of tumor progression. Having a
high tissue ascorbate level could help prevent formation of solid
tumors, slow tumor growth rates, inhibit aggressive tumor behav-
ior, and even aid in the treatment of established cancers. Despite
growing interest in ascorbate as a cancer treatment, there remains
a great deal of controversy over its clinical use. However, an objec-
tive evaluation of data obtained from systematic inquiry, with an
understanding of the underlying mechanisms would provide valu-
able insights to inform the debate. The studies summarized here
clearly indicate that further investigation of the use of ascorbate in
FIGURE 3 |The effect of plasma ascorbate availability on delivery to
remote tumor tissue and activity of the HIF-hydroxylases. Higher
plasma ascorbate results in increased penetration of remote and hypoxic
regions and the ability to down-regulate HIF-1 by promotion of the
regulatory hydroxylases. HIF-1 mediated changes that regulate the tumor
glycolytic phenotype, cell survival pathways, and angiogenesis could be
affected, decreasing tumor viability and improving treatment outcomes.
The epigenetic demethylases that also belong to the 2-OGDD family are
also likely to be affected but little is known about these processes in
cancer cells.
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enhancing 2-OGDD activity and combating tumor progression is
warranted.
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